Noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate.
This paper reviews the noncontraceptive benefits and therapeutic uses of depot medroxyprogesterone acetate (DMPA). Relevant articles were reviewed using a computerized Medline search of the literature from 1966 to 1995. Good evidence shows that DMPA use is associated with reduced iron-deficiency anemia, protection against pelvic inflammatory disease, protection from endometrial cancer and improved hematologic parameters among users with sickle cell disease. More studies are needed to fully assess DMPA's impact on other disorders.
Cullins
V E
VE
Department of Obstetrics and Gynecology, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland 21224, USA.
D018798:Anemia, Iron-Deficiency / Q000188:drug therapy; D000755:Anemia, Sickle Cell / Q000188:drug therapy; D003271:Contraceptive Agents, Female / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D016889:Endometrial Neoplasms / Q000517:prevention & control; D005260:Female; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use*; D000292:Pelvic Inflammatory Disease / Q000517:prevention & control
D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D017258:Medroxyprogesterone Acetate